Featured Event

GHTC is hosting an event "From lab to lives saved: How health innovation at USAID is advancing the journey to self-reliance" on August 14 in Washington, DC. The event will feature a fireside chat with USAID Chief of staff Bill Steiger and panel discussion with staff from the Global Health Bureau and nonprofit and private sector partners.

Learn More

PATH/Wendy Stone
GHTC Director quoted in The Verge on product development for emerging and infectious diseases

The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.

View

PATH
US FDA Approves New TB Drug in Treatment to Cure Practically Incurable XDR-TB

Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.

Learn More

PATH/Nguyen Ba Quang
GHTC Director quoted in the Los Angeles Times on FDA approval of a new drug for highly drug-resistant tuberculosis

The Los Angeles Times quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.

View

PATH/Katrina Peach
GHTC Director quoted in CIDRAP on FDA approval of a new drug for highly resistant tuberculosis

CIDRAP quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.

View

PATH/Rocky Prajapati
The European Sting crossposts GHTC commentary on UHC

The European Sting reposted a commentary piece co-authored by GHTC Director Jamie Bay Nishi, first published in World Economic Forum's Agenda, on the importance of public-private partnerships and innovation to achieving universal health coverage (UHC).

View
View All News

PATH
US FDA Approves New TB Drug in Treatment to Cure Practically Incurable XDR-TB

Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.

Learn More

PATH/Mike Wang
President Signs Bill Reinforcing Fight Against Disease Threats. Focus Now Turns to Funding.

This legislation is an important step forward in strengthening our nation’s preparedness against global disease threats. We applaud the Administration and Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiological and nuclear threats, but naturally occurring health threats as well.

View

GHTC
GHTC opens call for nominations for 2019 Innovating for Impact Awards

GHTC has opened nominations for its 2019 Innovating for Impact Awards. Now in its third year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is July 31, 2019.

Learn More

PATH/Eric Becker
Congress Takes Key Step to Reinforce Fight Against Disease Threats. Focus Now Turns to Funding.

The passage of PAHPAI is an important action by Congress to strengthen our nation’s preparedness against global disease threats. We applaud Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiologic and nuclear threats, but naturally occurring health threats as well.

Learn More

PATH/Gabe Bienczycki
WHO Member States Must Increase Investments in R&D for New Tools to Meet Urgent Health Challenges

Next week’s World Health Assembly will be setting priorities that have enormous life-altering implications for billions of people around the world. The Global Health Technologies Coalition (GHTC) is calling on World Health Organization (WHO) member states to increase investments in research and development (R&D), as new tools and technologies are essential for meeting urgent challenges, from achieving universal health coverage (UHC) to fighting antimicrobial resistance (AMR), including drug-resistant tuberculosis (DR-TB), and emerging threats like Ebola.

Learn More
View All Announcements
PATH/Matthew Dakin
Research Roundup: The first chlamydia vaccine passed a major test, a new drug approved for drug-resistant tuberculosis, and two new Ebola treatments prove highly effective in the DRC

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Satvir Malhotra
Research Roundup: A portable “cholera detection lab," Sabin acquires rights to develop Ebola and Marburg vaccines, and Uganda starts largest-ever Ebola vaccine trial

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Gabe Bienczycki
Research Roundup: A 'Google' for biomedical data, alarming surge in drug-resistant HIV, and CEPI partners with Valneva to develop Chikungunya vaccine

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Carib Nelson
Research Roundup: WHO recommends dolutegravir as the first-choice HIV treatment, an arm implant that may one day protect against HIV, and malaria drugs failing in Southeast Asia

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Gabe Bienczycki
Research Roundup: Wiping out mosquitoes on two Chinese islands, betting on biometrics to boost vaccination rates, and J&J to test HIV vaccine in US and Europe

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
View Breakthroughs Blog

PATH/Wendy Stone
GHTC Director quoted in The Verge on product development for emerging and infectious diseases

The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.

View

PATH/Nguyen Ba Quang
GHTC Director quoted in the Los Angeles Times on FDA approval of a new drug for highly drug-resistant tuberculosis

The Los Angeles Times quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.

View

PATH/Katrina Peach
GHTC Director quoted in CIDRAP on FDA approval of a new drug for highly resistant tuberculosis

CIDRAP quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.

View

PATH/Rocky Prajapati
The European Sting crossposts GHTC commentary on UHC

The European Sting reposted a commentary piece co-authored by GHTC Director Jamie Bay Nishi, first published in World Economic Forum's Agenda, on the importance of public-private partnerships and innovation to achieving universal health coverage (UHC).

View

Flickr: Diego Gurgel / Secom
Healio Infectious Disease News quotes GHTC Director on pandemic preparedness legislation

Healio Infectious Disease News quoted GHTC Director Jamie Bay Nishi in an article on the signing into law of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act.

View
View All GHTC in the Media

PATH/Ruhani Kaur
GHTC endorses Comprehensive TB Elimination Act

GHTC joined other advocates in endorsing the Comprehensive TB Elimination Act of 2019, which would enhance tuberculosis (TB) R&D at the National Institutes of Health and facilitate coordination of late stage R&D of new TB diagnostic, treatment, and prevention tools with the Biomedical Advanced Research and Development Authority.

PDF

PATH/Nguyen Ba Quang
GHTC statement on High-Level Meeting on Tuberculosis (TB) delivered at WHA

A statement by GHTC and partners calling on the World Health Organization and member states to close the US$1.3 billion gap in annual TB R&D funding was made at the 72nd World Health Assembly. The statement urges countries to invest in the development of new medicines and technologies to treat multidrug-resistant TB and to facilitate rapid and equitable access to these interventions.

View

PATH/Gabe Bienczycki
GHTC statement on pandemic influenza preparedness delivered at WHA

A statement by GHTC and partners encouraging innovative technologies and approaches to accelerate universal influenza vaccine research and development was made at the 72nd World Health Assembly. This statement recognizes pandemic influenza as a looming global health threat and encourages the World Health Organization and member states to increase investment and collaborative action to accelerate development of a universal flu vaccine.

View

CDC/Melissa Dankel
GHTC statement on UN High-Level Meeting on AMR delivered at WHA

A statement by GHTC and partners noting that innovation and R&D must be at the heart of any agenda to tackle AMR was delivered at the 72nd World Health Assembly. The statement applauds World Health Organization member states for recognizing the need for new antimicrobials, vaccines, and diagnostics, and urges continued progress on commitments made at the United Nations (UN) High-Level Meeting.

View

PATH
GHTC statement on Universal Health Coverage delivered at WHA

A statement by GHTC and partners emphasizing the importance of innovation and R&D as a central pillar of universal health coverage (UHC) was made at the 72nd World Health Assembly. The statement calls for the Political Declaration to include language to strengthen health systems down to the community level by investing in R&D to ensure quality care for all.

View
View All Advocacy Actions

Events

Community Event

11th Annual CUGH Conference
Consortium of Universities for Global Health
Learn More

Member Event

PATH/Georgina Goodwin
2019 Global Health Landscape Symposium
Global Health Council
Learn More
View All Current & Past Events

Stay Informed

Sign up to receive news and updates from GHTC.
Sign Up Now

Media Inquiries

Marissa Chmiola
Communications Officer
Global Health Technologies Coalition
mchmiola@ghtcoalition.org